OTC: SOLTF - Sosei Group Corporation

Yield per half year: -34.48%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Sosei Group Corporation

Extended chart Simple chart
Financial Markets by TradingView

About Sosei Group Corporation

Sosei Group Corporation develops biopharmaceutical products worldwide. Its marketed products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair to treat asthma; and ORAVI, an oropharyngeal candidiasis.

more details
The company's product pipeline consists of GPR35 agonist, for inflammatory bowel disease/GI disorders, which is in preclinical stage; HTL0016878 for Schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; and PF-07258669 for anorexia. Sosei Group Corporation has a strategic collaboration with AbbVie, Biohaven, Genentech, GSK, Takeda, Pfizer, Neurocrine Biosciences, Novartis, Verily, AstraZeneca, and Takeda. The company was incorporated in 1990 and is headquartered in Tokyo, Japan.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 0
Дивиденд ао 0.0673
Сайт https://soseiheptares.com
Цена ао 5.91
Change price per day: 0% (5.91)
Change price per week: 0% (5.91)
Change price per month: -9.36% (6.52)
Change price per 3 month: -9.36% (6.52)
Change price per half year: -34.48% (9.02)
Change price per year: -39.2% (9.72)
Change price per 3 year: -54.11% (12.88)
Change price per 5 year: -54.71% (13.05)
Change price per year to date: -4.02% (6.1575)
All parameters

Underestimation

Title Value Grade
P/S 9 1
P/BV 0.0122 10
P/E 325.54 1
EV/EBITDA -550.44 0
Total: 4.25

Efficiency

Title Value Grade
ROA, % -0.0325 0
ROE, % -0.0764 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0.5 5
Total: 1.31

Debt

Title Value Grade
Debt/EBITDA -1497.58 10
Total: 9.6

Growth impulse

Title Value Grade
Yield Revenue, % -98.77 0
Yield Ebitda, % -102.13 0
Yield EPS, % -104.42 0
Total: 0
More

Institutions Volume Share, %
Smallcap World Fund 1841200 2.06
Vanguard International Stock Index-Total Intl Stock Indx 997900 1.12
Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund 604000 0.68
iShares Core MSCI EAFE ETF 441300 0.49
iShares MSCI EAFE Small Cap ETF 284100 0.32
Vanguard Intl Equity Index Fds-FTSE All World ex U.S.Small Cap Index 278200 0.31
Schwab Strategic Tr-Schwab International Small Cap Equity ETF 149344 0.17
iShares Core MSCI Total International Stock ETF 129600 0.14
Vanguard International Stock Index-Pacific Stock Index 89400 0.1
iShares Core MSCI International Developed Markets ETF 62100 0.07



Head Job title Payment Year of birth
Mr. Christopher Cargill Representative Executive Officer, President, CEO & Director 1.25M 1984 (41 year)
Mr. Hironoshin Nomura Executive Officer, Executive VP & CFO N/A 1983 (42 years)
Mr. Kieran Johnson F.C.A. Executive Officer, Executive VP & Chief Accounting Officer N/A 1969 (56 years)
Mr. Toshihiro Maeda Executive VP & COO N/A 1979 (46 years)
Mr. Kazuhiko Yoshizumi Executive Officer, Executive VP & Chief Compliance Officer N/A 1954 (71 year)
Shinichiro Nishishita VP of Investor Relations & Head of Regulatory Disclosures N/A
Stacey Southall Associate Director & Head of Biophysics N/A
Ms. Candelle Chong Executive Officer, Executive VP, CEO Office & Chief of Staff N/A 1989 (36 years)
Dr. Satoshi Tanaka Exe. Off., Executive VP and President of Idorsia Pharmaceuticals Japan & Nxera Pharma Japan N/A 1957 (68 years)
Dr. Shinichi Tamura Founder & Chairman of the Board 1949 (76 years)

Address: Japan, Tokyo -, PMO Hanzomon - open in Google maps, open in Yandex maps
Website: https://soseiheptares.com